Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Operating Leases (2019 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Operating Leases for 8 consecutive years, with $16.9 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Leases fell 68.0% year-over-year to $16.9 million; the TTM value through Mar 2026 reached $16.9 million, down 68.0%, while the annual FY2025 figure was $21.8 million, 45.74% down from the prior year.
  • Operating Leases hit $16.9 million in Q1 2026 for Agios Pharmaceuticals, down from $21.8 million in the prior quarter.
  • Across five years, Operating Leases topped out at $94.1 million in Q1 2022 and bottomed at $16.9 million in Q1 2026.
  • Average Operating Leases over 5 years is $55.1 million, with a median of $57.0 million recorded in 2023.
  • Year-over-year, Operating Leases changed 0.0% in 2024 and then tumbled 68.0% in 2026.
  • Agios Pharmaceuticals' Operating Leases stood at $72.0 million in 2022, then decreased by 20.85% to $57.0 million in 2023, then fell by 29.45% to $40.2 million in 2024, then plummeted by 45.74% to $21.8 million in 2025, then dropped by 22.35% to $16.9 million in 2026.
  • According to Business Quant data, Operating Leases over the past three periods came in at $16.9 million, $21.8 million, and $26.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.